Matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in vesicoureteral reflux
Authors:
- 5 October 2011
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 27 (3) , 435-441
Abstract
The aim of this study was to investigate whether urine levels of matrix metalloproteinase 9 (uMMP9) and tissue inhibitor of metalloproteinase 1 (uTIMP1) are novel biomarkers of vesicoureteral reflux (VUR) and to determine the optimal cut-off levels of these enzymes to predict VUR in children. The study group consisted of 67 children with VUR and 20 healthy children. Urine MMP9 and TIMP1 levels were measured by an enzyme-linked immunosorbent assay. Children with VUR had significantly higher uMMP9 (1,539.8 vs. 256.4 pg/mL; p = 0.0001) and uTIMP1 (182 vs. 32.6 pg/mL; p = 0.0001) levels than healthy children. For the prediction of VUR, the sensitivity of uMMP9 was 67%, with a specificity of 85% [cut-off value 1,054 pg/mL; area under the curve (AUC) 0.77], and the sensitivity of uTIMP1 was 74%, with a specificity of 65% (cut-off value 18.7 pg/mL; AUC 0.73). Both uMMP9 and uTIMP1 levels were significantly higher in patients with renal scar (uMMP9: 3,117.3 vs. 1,234.15 pg/mL; p = 0.0001; uTIMP1: 551.05 vs. 128.64 pg/mL; p = 0.0001). Urine MMP9 levels had a sensitivity of 81.2%, with a specificity of 85% to predict renal scar in the VUR group (cut-off 1,054 pg/mL; AUC 0.88). The sensitivity of uTIMP1 was 75%, with a specificity of 90% to predict renal scar (cut-off 243.7 pg/mL; AUC 0.82). Based on these results, we suggest that uTIMP1 may be a useful marker to predict renal scarring with a different cut-off value from VUR and a high specificity at this cut-off point. Although uMMP9 seemingly cannot distinguish renal scar from VUR, the simultaneous increase in the level of both markers may indicate ongoing renal injury due to VUR.Keywords
This publication has 19 references indexed in Scilit:
- Cut‐off values for serum matrix metalloproteinase‐9: Is there a threshold to predict renal involvement for Henoch–Schonlein purpura in children?Nephrology, 2010
- MMP9 and SCF Protect from Apoptosis in Acute Kidney InjuryJournal of the American Society of Nephrology, 2009
- Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammationNephrology Dialysis Transplantation, 2008
- Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitisAmerican Journal of Physiology-Renal Physiology, 2007
- Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical stainingClinical and Experimental Nephrology, 2006
- Renal fibrosis: New insights into the pathogenesis and therapeuticsKidney International, 2006
- EXTRACELLULAR MATRIX DEGRADATION AND REDUCED NERVE SUPPLY IN REFLUXING URETERAL ENDINGSJournal of Urology, 2004
- TablesAmerican Journal of Kidney Diseases, 2002
- Etiology of chronic renal failure in Turkish childrenPediatric Nephrology, 1995
- Proteinases and glomerular matrix turnoverKidney International, 1992